#Fasttrack schedule 3 license#
#Fasttrack schedule 3 mac#

FastTrack Schedule is also available in compatible Mac and iOS versions.Ĭollaborate with both Windows and Mac team members and seamlessly consolidate schedules into a master file. Choose from over 50 industry-specific QuickStart Templates or simply create schedules from data in Excel, organizers, databases, and other project management programs including MS Project. Great for both new and experienced project managers, FastTrack Schedule 10's eye-catching schedules clearly show assignments, progress, and goals - keeping your team and clients informed and up-to-date.Įasier to use than typical project managers, FastTrack Schedule provides an instant framework for all your project details. Powerful tracking tools and dynamic status reports keep team members in sync, costs under control, and projects on schedule. The frequency of communication assures that questions and issues are resolved quickly, often leading to earlier drug approval and access by patients.FastTrack Schedule 10 makes it easy to plan, track, and manage projects. Once a drug receives Fast Track designation, early and frequent communication between the FDA and a drug company is encouraged throughout the entire drug development and review process. FDA will review the request and make a decision within sixty days based on whether the drug fills an unmet medical need in a serious condition. The request can be initiated at any time during the drug development process. BLA or NDA review usually does not begin until the drug company has submitted the entire application to the FDAįast Track designation must be requested by the drug company.

#Fasttrack schedule 3 license#

Rolling Review, which means that a drug company can submit completed sections of its Biologic License Application (BLA) or New Drug Application (NDA) for review by FDA, rather than waiting until every section of the NDA is completed before the entire application can be reviewed.

More frequent written communication from FDA about such things as the design of the proposed clinical trials and use of biomarkersĮligibility for Accelerated Approval and Priority Review, if relevant criteria are met More frequent meetings with FDA to discuss the drug's development plan and ensure collection of appropriate data needed to support drug approval Improving the diagnosis of a serious condition where early diagnosis results in an improved outcomeĭecreasing a clinical significant toxicity of an available therapy that is common and causes discontinuation of treatmentĪbility to address emerging or anticipated public health needĪ drug that receives Fast Track designation is eligible for some or all of the following: Showing superior effectiveness, effect on serious outcomes or improved effect on serious outcomesĪvoiding serious side effects of an available therapy.If there are available therapies, a fast track drug must show some advantage over available therapy, such as: However, diseases such as epilepsy, depression and diabetes are also considered to be serious conditions.įilling an unmet medical need is defined as providing a therapy where none exists or providing a therapy which may be potentially better than available therapy.Īny drug being developed to treat or prevent a condition with no current therapy obviously is directed at an unmet need. AIDS, Alzheimer’s, heart failure and cancer are obvious examples of serious conditions. Fast Track addresses a broad range of serious conditions.ĭetermining whether a condition is serious is a matter of judgment, but generally is based on whether the drug will have an impact on such factors as survival, day-to-day functioning, or the likelihood that the condition, if left untreated, will progress from a less severe condition to a more serious one. The purpose is to get important new drugs to the patient earlier. Fast track is a process designed to facilitate the development, and expedite the review of drugs to treat serious conditions and fill an unmet medical need.